Journal of Physical Chemistry & Biophysics
Open Access

Deep Tissue Photodynamic Therapy: A Novel Approach using X-ray Activated Nanoplatforms

Gilberto Veiri^{* *}Correspondence: Gilberto Veiri, Department of Chemistry, National University of Villa Maria, Cordoba, Argentina, Email:

Author info »

Description

In the area of modern medicine, the question for targeted and effective treatments for diseases like cancer has led to greater innovations in nanotechnology. Among these innovations, X-ray activated nanoplatforms have emerged as potential tools for revolutionizing Photodynamic Therapy (PDT), particularly in the context of treating deep-seated tumors. In this comprehensive study, we move into the principles, applications, challenges and future prospects of X-ray activated nanoplatforms for deep tissue PDT [1].

Photodynamic therapy

Before moving into X-ray activated nanoplatforms, it's essential to hold the fundamentals of photodynamic therapy-a minimally invasive treatment modality with the potential for cancer therapy. PDT involves the administration of a photosensitizing agent, which selectively accumulates in tumor tissues, followed by the localized application of light of a specific wavelength. This light activates the photosensitizer, leading to the generation of Reactive Oxygen Species (ROS) that induce tumor cell death through oxidative stress and apoptosis [2].

Limitations of conventional photodynamic therapy

While PDT has shown ability in treating superficial tumors, its efficacy in targeting deep-seated or metastatic lesions is obstructed by the limited tissue penetration of light. Conventional light sources, such as lasers, struggle to penetrate deep into tissues, restricting the application of PDT to surface or accessible tumors. Overcoming this limitation requires innovative strategies to deliver light to deeper tissue layers while maintaining the selectivity and specificity of PDT [3].

X-ray activated nanoplatforms

X-ray activated nanoplatforms represent an ideal shift in the field of PDT, offering a solution to the challenge of deep tissue treatment. These nanoplatforms are engineered to incorporate both a photosensitizer and a biocompatible nanocarrier, allowing for targeted delivery to tumor sites. What sets them apart is their ability to control the energy of X-rays, which possess superior tissue penetration capabilities compared to visible light, enabling activation of the photosensitizer within deep tissues [4].

Mechanism of action

The mechanism of X-ray activated nanoplatforms involves a multi-step process that begins with the selective accumulation of nanoparticles within tumor tissues, facilitated by passive or active targeting strategies. Once localized, the nanoparticles absorb X-ray radiation, leading to the emission of secondary electrons and the production of ROS through radiolysis of water or direct energy transfer. These ROS induce cytotoxic effects, selectively destroying tumor cells while sparing surrounding healthy tissue [5].

Advantages of X-ray activation

The use of X-rays as an activation source extend to several advantages to nanoplatform based PDT. Firstly, X-rays can penetrate deeper into tissues, allowing for the treatment of tumors located beyond the reach of conventional light sources. This deep tissue penetration is particularly advantageous for addressing metastatic lesions or tumors situated in anatomically challenging locations. Additionally, X-ray activation enables precise spatial and temporal control over PDT, minimizing offtarget effects and enhancing therapeutic efficacy [6].

Engineering X-ray activated nanoplatforms

Designing effective X-ray activated nanoplatforms requires careful consideration of several key factors, including the choice of photosensitizer, nanocarrier material and targeting strategy. Photosensitizers with high X-ray absorption coefficients and efficient ROS generation capabilities are preferred, ensuring optimal therapeutic outcomes. Nanocarriers such as liposomes, polymeric nanoparticles or inorganic materials like gold nanoparticles, provide a stable and biocompatible platform for drug delivery and enhance tumor accumulation through passive or active targeting mechanisms [7].

Challenges and considerations

Despite their ability, X-ray activated nanoplatforms face several challenges that must be addressed to realize their full potential in clinical practice. One such challenge is optimizing the balance between X-ray absorption and ROS generation, as excessive ROS production can lead to off-target toxicity. Furthermore, achieving precise spatiotemporal control over X-ray activation requires advancements in imaging and radiation delivery technologies. Additionally, concerns regarding the long-term safety and biocompatibility of nanomaterials necessitate thorough preclinical evaluation and regulatory scrutiny [8].

Preclinical and clinical studies

The development of X-ray activated nanoplatforms has progressed rapidly in preclinical settings, with numerous studies demonstrating their efficacy in animal models of cancer. These studies have shown potential results in terms of tumor regression, prolonged survival and minimal systemic toxicity. Translating these findings into clinical practice requires careful evaluation through well-designed clinical trials, which are currently underway to assess the safety, efficacy and feasibility of X-ray activated nanoplatforms in human patients [9].

Future directions

The future of X-ray activated nanoplatforms for deep tissue PDT appears bright, with ongoing research focused on overcoming existing challenges and expanding their clinical applications. Advances in nanomaterial design, imaging techniques and radiation therapy modalities hold the capability of further enhancing the efficacy and safety of these innovative therapeutics. As our understanding of cancer biology and nanotechnology continues to evolve, X-ray activated nanoplatforms are assured to play a transformative role in the fight against cancer, offering new hope for patients with advanced or treatment-resistant disease [10].

Conclusion

X-ray activated nanoplatforms represent a developing approach to overcome the limitations of conventional photodynamic therapy and expanding the reach of this potential treatment modality to deep tissue tumors. By controlling the power of Xrays to activate photosensitizers within tumor tissues, these nanoplatforms offer a unique combination of deep tissue penetration, spatial precision and therapeutic efficacy. While challenges remain, ongoing research and clinical trials hold the potential to open the full therapeutic potential of X-ray activated nanoplatforms, bringing us closer to realizing the vision of personalized and targeted cancer therapy.

References

1. Gadzhimagomedova Z, Zolotukhin P, Kit O, Kirsanova D, Soldatov A. Nanocomposites for X-ray photodynamic therapy. Int J Mol Sci. 2020;21(11):4004.

   [Crossref] [Google Scholar] [Pubmed]

2.  Sun B, Rahmat JN, Zhang Y. Advanced techniques for performing photodynamic therapy in deep-seated tissues. Biomaterials. 2022;291:121875.

   [Crossref] [Google Scholar] [Pubmed]

3. Luo Z, Mao D, Li X, Luo J, Gong C, Liu X. Lanthanide-based nanoparticles for cancer phototherapy. Coord Chem Rev. 2024;508:215773.

   [Crossref] [Google Scholar]

4. Wang GD, Nguyen HT, Chen H, Cox PB, Wang L, Nagata K, et al. X-ray induced photodynamic therapy: A combination of radiotherapy and photodynamic therapy. Theranostics. 2016;6(13):2295.

   [Crossref] [Google Scholar] [Pubmed]

5. Hu J, Tang YA, Elmenoufy AH, Xu H, Cheng Z, Yang X. Nanocomposite‐based photodynamic therapy strategies for deep tumor treatment. Small. 2015;11(44):5860-5887.

   [Crossref] [Google Scholar] [Pubmed]

6. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61(4):250-281.

   [Crossref] [Google Scholar] [Pubmed]

7. Chen H, Wang GD, Chuang YJ, Zhen Z, Chen X, Biddinger P, et al. Nanoscintillator-mediated X-ray inducible photodynamic therapy for in vivo cancer treatment. Nano lett. 2015;15(4):2249-2256.

   [Crossref] [Google Scholar] [Pubmed]

8. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90(12):889-905.

   [Crossref] [Google Scholar]

9. Ito H, Shoji Y, Ueno M, Matsumoto KI, Nakanishi I. Photodynamic therapy for X-ray-induced radiation-resistant cancer cells. Pharmaceutics. 2023;15(11):2536.

   [Crossref] [Google Scholar] [Pubmed]

10. He L, Yu X, Li W. Recent progress and trends in X-ray-induced photodynamic therapy with low radiation doses. ACS Nano. 2022;16(12):19691-721.

    [Crossref] [Google Scholar] [Pubmed]